Piyush Mittal, MD
Internal Medicine · Lubbock, TXNPI 1447250923
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 556 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,971 and has fallen 55.0% since, to $887 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 556 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- Novo Nordisk$681
- Novartis$636
- Abbott$583
- Lilly USA, LLC$531
- plus $5K from 42 others
What the payments were for
- Food & beverage$9,05198%
- Education$2132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,264 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 13 | $576,102 |
| OzempicSemaglutide | 169 | $176,853 |
| MounjaroTirzepatide | 97 | $119,836 |
| EliquisApixaban | 165 | $97,517 |
| XifaxanRifaximin | 26 | $57,895 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $56,653 |
| JardianceEmpagliflozin | 58 | $50,149 |
| XareltoRivaroxaban | 26 | $33,888 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $26,828 |
| Repatha SureclickEvolocumab | 31 | $25,246 |
| JanuviaSitagliptin Phosphate | 37 | $23,377 |
| TrulicityDulaglutide | 15 | $21,489 |
| EntrestoSacubitril/Valsartan | 34 | $19,559 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $17,439 |
| LinzessLinaclotide | 19 | $16,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $246 | $576,10213 claims |
| Novo NordiskOzempic | $681 | $176,853169 claims |
| Lilly USA, LLCMounjaro, Trulicity | $531 | $141,325112 claims |
| PfizerEliquis | $49 | $97,517165 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $266 | $61,45485 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $115 | $57,89526 claims |
| MerckJanumet, Januvia | $191 | $50,20553 claims |
| Boehringer IngelheimJardiance | $211 | $50,14958 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $157 | $35,52052 claims |
| Johnson & JohnsonXarelto | $368 | $33,88826 claims |
| NovartisEntresto | $636 | $19,55934 claims |
| AbbVieLinzess | $1,084 | $16,16819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Lubbock
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.